Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

AIMS: Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target‐antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Autores principales: Lioger, Bertrand, Edupuganti, Soujanya Ratna, Mulleman, Denis, Passot, Christophe, Desvignes, Céline, Bejan‐Angoulvant, Théodora, Thibault, Gilles, Gouilleux‐Gruart, Valérie, Mélet, Julien, Paintaud, Gilles, Ternant, David
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacokinetic Dynamic Relationships
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5510084/
https://ncbi.nlm.nih.gov/pubmed/28230269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13270
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares